RECIPROCAL CROSS-RESISTANCE IN HUMAN RHABDOMYOSARCOMAS SELECTED INVIVO FOR PRIMARY RESISTANCE TO VINCRISTINE AND L-PHENYLALANINE MUSTARD
- 1 December 1987
- journal article
- research article
- Vol. 47 (23) , 6288-6293
Abstract
Primary resistance to vincristine (VCR) has been selected in rhabdomyosarcoma xenograft HxRh12 by sequential administration of VCR at 1.5 and subsequently 3 mg/kg/passage. The resistant tumor (HxRh12/VCR-3) was approximately 4-fold resistant to VCR and resistance was stable in the absence of selecting pressure (< 2 yr). HxRh12/VCR-3 was 2- to 3-fold cross-resistant to L-phenylalanine mustard (L-PAM) but only slightly cross-resistant to ifosfamide. To determine whether selection for primary resistance to L-PAM conferred cross-resistance to VCR we selected an L-PAM-resistant subline of rhabdomyosarcoma xenograft HxRh28 (HxRh28/L-PAM-13). This tumor was 2- to 3-fold resistant to L-PAM and 3-(p-fluorophenyl)-L-alanyl-3-[m-bis-(2-chloroethyl)-aminophenyl]-L-alanyl-L-methionine ethoxyhydrocloride, cross-resistant to cyclophosphamide and ifosfamide, and completely resistant to VCR under in vivo conditions. Pharmacokinetic studies in HxRh12/VCR-3 showed decreased retention of [G-3H]VCR but not alteration in metabolism. Expression of mdr1, a gene that encodes P-glycoprotein, associated with the multiple drug resistance phenotype, was examined. Expression of mdr1 was detected in both HxRh12 and HxRh28 tumors, sensitive to VCR, but there was no increased in expression in tumors selected for primary resistance to VCR or L-PAM. Data suggest that mechanisms other than those associated with "classical" multiple drug resistance confer resistance in these tumors. In clinical evaluation against childhood rhabdomyosarcoma, L-PAM has demonstrated only slight activity in patients relapsing on conventional therapy (including VCR) but demonstrated marked activity in patients with advanced previously untreated disease. It appears likely, therefore, that cross-resistance between VCR and L-PAM as demonstrated in this model may have clinical significance.This publication has 26 references indexed in Scilit:
- Growth and Characterization of Childhood Rhabdomyosarcomas as Xenografts23JNCI Journal of the National Cancer Institute, 1982
- Development of resistance to vincristine in a childhood rhabdomyosarcoma growing in immune-deprived miceInternational Journal of Cancer, 1981
- SELECTION AND CHARACTERIZATION OF CHINESE-HAMSTER OVARY CELL MUTANTS RESISTANT TO MELPHALAN (L-PHENYLALANINE MUSTARD)1981
- Number and evolutionary conservation of α- and β-tubulin and cytoplasmic β- and γ-actin genes using specific cloned cDNA probesCell, 1980
- RESISTANCE PATTERNS OF WALKER CARCINOSARCOMA 256 AND OTHER RODENT TUMORS TO CYCLOPHOSPHAMIDE AND L-PHENYLALANINE MUSTARD1980
- EVIDENCE FOR ACTIVE-TRANSPORT OF MELPHALAN BY 2 AMINO-ACID CARRIERS IN L5178Y LYMPHOBLASTS INVITRO1979
- Absence of cross-resistance to alkylating agents in cyclophosphamide-resistant L1210 leukemiaPublished by Elsevier ,1978
- DIFFERENCES BETWEEN MELPHALAN AND NITROGEN-MUSTARD IN FORMATION AND REMOVAL OF DNA CROSS-LINKS1978
- INVIVO CHARACTERISTICS OF RESISTANCE AND CROSS-RESISTANCE OF AN ADRIAMYCIN-RESISTANT SUBLINE OF P388 LEUKEMIA1978
- Amino acid-conferred protection against melphalan—Characterization of melphalan transport and correlation of uptake with cytotoxicity in cultured L1210 murine leukemia cellsBiochemical Pharmacology, 1978